It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The etiology of recurrent pregnancy loss (RPL) is complex and multifactorial and in half of patients it remains unexplained (U-RPL). Recently, low-molecular-weight heparin (LMWH) has gained increasing relevance for its therapeutic potential. On this regard, the aim of this systematic review and meta-analysis is to analyze the efficacy of low molecular weight heparin (LMWH) from the beginning of pregnancy in terms of live birth rates (LBR) in U-RPL. Registered randomized controlled trials (RCTs) were included. We stratified findings based on relevant clinical factors including number of previous miscarriages, treatment type and control type. Intervention or exposure was defined as the administration of LMWH alone or in combination with low-dose aspirin (LDA). A total of 6 studies involving 1016 patients were included. The meta-analysis results showed that LMWH used in the treatment of U-RPL was not associated with an increase in LBR with a pooled OR of 1.01, a medium heterogeneity (26.42%) and no publication bias. Results of other sub-analyses according to country, treatment type, and control type showed no significant effect of LMWH on LBR in all subgroups, with a high heterogeneity. The results highlight a non-significant effect of LMWH in U-RPL on LBR based on moderate quality evidence.
Registration number: PROSPERO: (https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022326433).
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 Università Vita-Salute San Raffaele, Milan, Italy (GRID:grid.15496.3f) (ISNI:0000 0001 0439 0892)
2 Università Vita-Salute San Raffaele, Milan, Italy (GRID:grid.15496.3f) (ISNI:0000 0001 0439 0892); IRCCS San Raffaele Scientific Institute, Department of Obstetrics and Gynecology, Milan, Italy (GRID:grid.15496.3f) (ISNI:0000 0004 1784 8390)
3 IRCCS San Raffaele Scientific Institute, Division of Immunology, Transplantation and Infectious Diseases, Milan, Italy (GRID:grid.18887.3e) (ISNI:0000000417581884)
4 IRCCS San Raffaele Scientific Institute, Department of Obstetrics and Gynecology, Milan, Italy (GRID:grid.18887.3e) (ISNI:0000 0004 1784 8390)
5 Università Vita-Salute San Raffaele, Milan, Italy (GRID:grid.15496.3f) (ISNI:0000 0001 0439 0892); IRCCS San Raffaele Scientific Institute, Division of Immunology, Transplantation and Infectious Diseases, Milan, Italy (GRID:grid.18887.3e) (ISNI:0000000417581884)
6 IRCCS San Raffaele Scientific Institute, Reproductive Sciences Laboratory, Milan, Italy (GRID:grid.18887.3e) (ISNI:0000000417581884)
7 Humanitas University, Department of Biomedical Sciences, Rozzano, Italy (GRID:grid.452490.e) (ISNI:0000 0004 4908 9368); IRCCS Humanitas Research Hospital, Division of Gynecology and Reproductive Medicine, Department of Gynecology, Fertility Center, Rozzano, Italy (GRID:grid.417728.f) (ISNI:0000 0004 1756 8807)